Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreas, Darian, Tosoian, Jeffrey J., Landis, Patricia, Wolf, Sacha, Glavaris, Stephanie, Lotan, Tamara L., Schaeffer, Edward M., Sokoll, Lori J., Ross, Ashley E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527/
https://www.ncbi.nlm.nih.gov/pubmed/27335798
http://dx.doi.org/10.1016/j.eucr.2016.04.012
_version_ 1782437843889553408
author Andreas, Darian
Tosoian, Jeffrey J.
Landis, Patricia
Wolf, Sacha
Glavaris, Stephanie
Lotan, Tamara L.
Schaeffer, Edward M.
Sokoll, Lori J.
Ross, Ashley E.
author_facet Andreas, Darian
Tosoian, Jeffrey J.
Landis, Patricia
Wolf, Sacha
Glavaris, Stephanie
Lotan, Tamara L.
Schaeffer, Edward M.
Sokoll, Lori J.
Ross, Ashley E.
author_sort Andreas, Darian
collection PubMed
description The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.
format Online
Article
Text
id pubmed-4909527
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49095272016-06-22 Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer Andreas, Darian Tosoian, Jeffrey J. Landis, Patricia Wolf, Sacha Glavaris, Stephanie Lotan, Tamara L. Schaeffer, Edward M. Sokoll, Lori J. Ross, Ashley E. Urol Case Rep Oncology The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer. Elsevier 2016-05-26 /pmc/articles/PMC4909527/ /pubmed/27335798 http://dx.doi.org/10.1016/j.eucr.2016.04.012 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Andreas, Darian
Tosoian, Jeffrey J.
Landis, Patricia
Wolf, Sacha
Glavaris, Stephanie
Lotan, Tamara L.
Schaeffer, Edward M.
Sokoll, Lori J.
Ross, Ashley E.
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title_full Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title_fullStr Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title_full_unstemmed Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title_short Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
title_sort elevated prostate health index (phi) and biopsy reclassification during active surveillance of prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527/
https://www.ncbi.nlm.nih.gov/pubmed/27335798
http://dx.doi.org/10.1016/j.eucr.2016.04.012
work_keys_str_mv AT andreasdarian elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT tosoianjeffreyj elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT landispatricia elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT wolfsacha elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT glavarisstephanie elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT lotantamaral elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT schaefferedwardm elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT sokolllorij elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer
AT rossashleye elevatedprostatehealthindexphiandbiopsyreclassificationduringactivesurveillanceofprostatecancer

Ejemplares similares